Orum Therapeutics오름테라퓨틱
475830 · KOSDAQ · ₩475830 · 오름테라퓨틱
₩15,320▼ ₩490 (3.10%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Revenue | ₩24M | ₩0 | ₩558,176 | ₩16M | ₩4.2M | ₩3M |
| Operating income | −₩15B | −₩18B | −₩18B | −₩14B | −₩10B | −₩9.6B |
| Net income | ₩63B | −₩15B | −₩16B | −₩14B | −₩3.8B | −₩8.6B |
| Net income to shareholders | ₩63B | −₩15B | −₩16B | −₩14B | −₩3.8B | −₩8.6B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Total assets | ₩292B | ₩313B | ₩169B | ₩182B | ₩186B | ₩192B |
| Current assets | ₩256B | ₩277B | ₩134B | ₩150B | ₩154B | ₩161B |
| Cash and equivalents | ₩114B | ₩113B | ₩4.1B | ₩16B | ₩5.8B | ₩7.4B |
| Total liabilities | ₩106B | ₩193B | ₩38B | ₩37B | ₩29B | ₩30B |
| Current liabilities | ₩82B | ₩169B | ₩16B | ₩15B | ₩6.4B | ₩5.7B |
| Borrowings | ₩8.1B | ₩12B | ₩12B | ₩12B | ₩3.5B | ₩2.5B |
| Total equity | ₩186B | ₩120B | ₩131B | ₩145B | ₩157B | ₩162B |
| Shareholders' equity | ₩186B | ₩120B | ₩131B | ₩145B | ₩157B | ₩162B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Cash from operations | −₩19B | −₩15B | −₩12B | −₩6.3B | −₩11B | −₩7.3B |
| Free cash flow | −₩19B | −₩15B | −₩12B | −₩6.3B | −₩11B | −₩7.3B |
Consolidated where available. Amounts in won.
Also known as: Orum Therapeutics / 오름테라퓨틱 / 475830 / KRX:475830
Source: KRX statistical information